Ligero, Marta http://orcid.org/0000-0001-9824-7316
Gielen, Bente
Navarro, Victor http://orcid.org/0000-0001-6925-4605
Cresta Morgado, Pablo
Prior, Olivia http://orcid.org/0009-0000-4913-6716
Dienstmann, Rodrigo
Nuciforo, Paolo http://orcid.org/0000-0003-1380-0990
Trebeschi, Stefano
Beets-Tan, Regina
Sala, Evis
Garralda, Elena
Perez-Lopez, Raquel http://orcid.org/0000-0002-9176-0130
Funding for this research was provided by:
Fundación BBVA (53/2021)
Prostate Cancer Foundation (18YOUN19)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (PI18/01395 and PI21/01019)
CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, Asociacion Española Contra el Cancer
PERIS PIF-Salut Grant
"la Caixa" Foundation
Article History
Received: 21 September 2023
Accepted: 26 January 2024
First Online: 21 February 2024
Competing interests
: ES, has received speakers fees from GE healthcare and is a co-founder and shareholder of Lucida Medical Ltd. EG declares research funding from Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene, Janssen. EG also reports consultant or advisor role for Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte, Medscape and speaker bureau from Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly, Novartis, SeaGen. RD declares advisory role for Roche, Foundation Medicine, received a speaker’s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Janssen, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead and research grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline and AstraZeneca. PN declares advisory or consultat role for MSD ONCOLOGY, BAYER and speaker’s fee from Novartis. No other competing interests are disclosed by any author.